Asset Details
Do you wish to reserve the book?
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
Do you wish to request the book?
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
2018
Overview
In a trial, patients with moderate to severely advanced idiopathic pulmonary fibrosis were treated with nintedanib plus sildenafil or nintedanib alone, with the goal of decreasing IPF symptoms. There were no between-group differences in any of three symptom measures.
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Dyspnea
/ Enzyme Inhibitors - adverse effects
/ Enzyme Inhibitors - therapeutic use
/ Female
/ Fibrosis
/ Humans
/ Idiopathic Pulmonary Fibrosis - drug therapy
/ Idiopathic Pulmonary Fibrosis - mortality
/ Idiopathic Pulmonary Fibrosis - physiopathology
/ Male
/ Patients
/ Phosphodiesterase 5 Inhibitors - adverse effects
/ Phosphodiesterase 5 Inhibitors - therapeutic use
/ Protein-Tyrosine Kinases - antagonists & inhibitors
/ Pulmonary Gas Exchange - drug effects
/ Safety
/ Sildenafil Citrate - adverse effects
